<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272738</url>
  </required_header>
  <id_info>
    <org_study_id>TatsuyaIoka2013</org_study_id>
    <secondary_id>UMIN 000012254</secondary_id>
    <nct_id>NCT02272738</nct_id>
  </id_info>
  <brief_title>A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer</brief_title>
  <official_title>A Phase I Study of Chemoradiotherapy Using Gemcitabine Plus Nab-paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka Medical Center for Cancer and Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka Medical Center for Cancer and Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical safety and efficacy of Gemcitabine plus
      nab-Paclitaxel chemoradiotherapy and to determine the Maximal Tolerated Dose (MTD) for
      unresectable locally advanced pancreatic adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine plus nab-Paclitaxel is one of the standard chemotherapy for metastatic pancreatic
      adenocarcinoma. Gemcitabine plus nab-Paclitaxel realize the favorable anti-tumor effect and
      tolerable toxicity. Gemcitabine plus nab-Paclitaxel is a promising regimen for concurrent
      chemoradiotherapy, but the investigators need to know the safety in the case of the
      concurrent chemoradiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>1 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival time</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine, Nab-Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conformal phase I study using 3 plus 3 method.
Chemoradiotherapy while Gemcitabine, Nab-Paclitaxel are administered.
Both Gemcitabine and Nab-Paclitaxel are an interventional agents in this arm.
Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
Radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.</description>
    <arm_group_label>Gemcitabine, Nab-Paclitaxel</arm_group_label>
    <other_name>Gemcitabine ；gemzer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.</description>
    <arm_group_label>Gemcitabine, Nab-Paclitaxel</arm_group_label>
    <other_name>Nab-Paclitaxel ；Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced pancreatic cancer

          -  Locally advanced pancreatic cancer is defined as the presence of a surgically
             unresectable tumor(involving the celiac axis or the superior mesenteric artery)

          -  Performance Status:0-1(ECOG)

          -  Patients of age =&gt;20 and 75&gt;

          -  White Blood Cell (WBC) &gt;=3,500/mm3,12,000/mm3,

               -  Neutrophils &gt;=1,500/mm3, platelets=100,000/mm3,

               -  Hemoglobin &gt;=9.5 g/dl,

               -  GOT &lt;/=2.0 X Upper Limit Number (ULN),

               -  Glutamate Pyruvate Transaminase (GPT) &lt;/=2.0 X ULN,

               -  Alkaline Phosphatase (ALP) &lt;/=2.0 X ULN,

               -  Total bilirubin &lt;=1.5mg/dl,

               -  Serum creatinine &lt;=1.2mg/dl,

               -  Creatinine clearance&gt;=50 ml/min

               -  arterial O2 pressure (PaO2) &gt;=70torr or arterial O2 saturation (SpO2) &gt;=96%

          -  Life expectancy more than 3 months.

          -  Written informed consent.

        Exclusion Criteria:

          -  Active infection

          -  Lung fibrosis or intestinal pneumonia detectable on chest X-ray and CT

          -  Severe complication (heart disease, cirrhosis, diabetes)

          -  Myocardial infarction within 3 months

          -  Active synchronous or metachronous malignancy

          -  Pregnant or lactation women, or women with known or suspected pregnancy

          -  Symptomatic brain metastasis

          -  History of severe drug allergy

          -  Peripheral neuropathy

          -  Patients who are judged inappropriate for the entry into the study by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatsuya Ioka, MD</last_name>
    <role>Study Director</role>
    <affiliation>Osaka Medical Center for Cancer and Cardiovascular Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>November 19, 2017</last_update_submitted>
  <last_update_submitted_qc>November 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

